Pharmacogenetic Testing Market Synopsis:
Pharmacogenetic Testing Market Size Was Valued at USD 13.20 Billion in 2023, and is Projected to Reach USD 28.95 Billion by 2032, Growing at a CAGR of 9.12% From 2024-2032.
The Pharmacogenetic Testing Market is the genetic testing that is used to determine the effects of the specific drugs on an individual. This testing helps the health care providers to determine which drugs and the dosage are going to affect a specific patient in a positive way depending on their gene. Pharmacogenetic testing is well utilized in individualized medicine and to increase the efficacy of treatments, and to minimize adverse drug effect and also in selection of drugs and doses.
The market of pharmacogenetic testing, of course, has expanded dramatically in its pace and scale as the need for individualized treatment increases across the globe. The kind of testing helps to make predictions of the actual effectiveness and safety of doses for human usage and assist the doctors in arriving at the right decisions regarding the drugs to use on specific patients. The developments in the gene technology and genetic research over the many years have led to remarkable growth of the market for research and clinics across numerous fields such as oncology, cardiology, neurology and psychiatric. Pharmacogenetic testing has better adoption in the developed regions as these regions have upgraded healthcare infrastructure which supports the latest diagnostics and adopts the precision/drug metabolism based medicine systems. Pharmaceutical manufacturers are also interested in this market; pharmacogenetic information is useful for development of drugs with suitable targets as well as effective avoidance of high drug failure rates.
The market is divided into various technologies and applications; PCR and DNA sequencing are also used in testing in this market. Efforts to offer personalized treatments for patients are rising due to the number of genetic data sets are available at the population level and pharmacogenetic testing. Moreover the backing from regulating bodies which have realized that pharmacogenetic testing helps in enhancing patient care, have also contributed for further growth. Nonetheless, the market faces some constraints such as the high costs of the services as well as poor awareness of the services in some parts of the world and there are factors that make this market to grow such as the changing face of the healthcare where more focus is now being placed strictly on customization.
Pharmacogenetic Testing Market Trend Analysis:
Growing Adoption of Pharmacogenetic Testing in Oncology
-
Pharmacogenetic testing has recently emerged as an essential component for targeted cancer treatment as seen in oncology practice. Chemotherapy and targeted therapies are some treatments for cancer that is characterized by diverse effectiveness and considerable side effects. It can be used to determine who are at high risk within a cancer population which genetic variants affect drug metabolism and response and tailor therapies based on a patient’s genetics. This change has enhanced the treatment consequences and minimized the risk of side effects where pharmacogenetic testing plays an essential role for oncology treatment.
- The call for pharmacogenetic testing of drugs used in oncology has been occasioned by the increase in the incidence of cancer and the resulting need for treatments that are more effective and with lesser toxicity levels. There are also such factors as increased sensible targeting of drugs that are compatible with an individual’s genetic map, owing to research from pharmaceutical companies, hence increasing the market. Studies in cancer pharmacogenomics have proved fruitful in providing information that has helped in creation of new treatments with less toxicity. With the future advancements in the field of precision medicine, pharmacogenetics testing is going to be even more a crucial part when it comes to treatment of cancer.
Expanding Applications in Neurology and Psychiatry
-
Pharmacogenetic testing is being incorporated in neurology and psychiatry more and more leading to significant possibilities of market expansion. These illnesses include neurological and psychiatric diseases where patients are most likely to be prescribed agents for a long time, and the patients may be on a combination of medications. These regimens can be optimized or modified via pharmacogenetic testing of patients; this enhances the outcomes of drugs and the reduction in side effects, which is especially wanting in those patients. This approach may provide useful information to clinicians by utilising genetic variations to predict how a patient will react to different psychotropic or neurologic drugs.
- Increasing pharmacogenetic utilization in neurology and psychiatry should enhance patient compliance and result. The knowledge about the genetic aspects to the metabolism of drugs, the clinician is in a position to choose the right drug and dose, thereby cutting on the time of experimentation, and increasing on the success of the treatment. The number of health care professionals and patients gaining knowledge about pharmacogenetics and its application will further generate a large market for pharmacogenetic testing in these fields.
Pharmacogenetic Testing Market Segment Analysis:
Pharmacogenetic Testing Market is Segmented on the basis of Technology, Application, End User, and Region.
By Technology, Polymerase Chain Reaction (PCR) segment is expected to dominate the market during the forecast period
-
Several technologies are used in pharmacogenetic testing and among them includes PCR, DNA sequencing and the microarray. PCR is often employed since it is a fast way of obtaining large quantities of DNA samples to differentiate gene types affecting drug response. DNA sequencing, however, is a more whole systems method which allows the observation of more genetic changes that may affect the efficacy and safety of medications. Conversely, microarrays enable the analysis of a large number of genes at once, giving a more generalised genetic background related to several drugs.
- Both of these technologies are integrated with each other and are usually employed side by side to give a comprehensive analysis of a patient’s pharmacogenetic makeup. There are occasions when the sequences of one gene are analyzed, while in other cases numerous sequences of different genes are examined; the demand of the particular test also plays a vital role not forgetting the costs of the technologies. Due to such advancements, these technologies are believed to contribute to extension of the pharmacogenetic testing precision, speed, and affordability.
By Application, Oncology segment expected to held the largest share
-
Pharmacogenetic testing is used in many therapeutic specialization sections like oncology, cardiovascular diseases, neurology, psychiatry, and pain management. In oncology, testing can assist to determine gene mutations relating to a patient’s response to cancer treatment to enhance therapies with better results. In cardiovascular diseases, pharmacogenetic testing can be useful for actions like the use of statins and blood thinners, since side effects may occur.
- Neurology and psychiatry constitute two new generations for pharmacogenetics, as they may be used to try and find the most suitable drug match for people with neurological or mental disorders. Another application of the pharmacogenetic testing is in pain management, with specific reference to opioids since its use impacts on side effects and a risk of dependency. Entirely, these applications supplement the gigantic and diverse versatility of pharmacogenetic testing seriously enhancing healthcare in variety of courses.
Pharmacogenetic Testing Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
Thus, North America remains to be the most leading region in the pharmacogenetic testing market as a result of improving the health care infrastructure, high level of investments in the genetic research and favorably high indicator of adoption of personalized medicine. The healthcare system in both the U.S. and Canada can thus fully endorse the application of various technologic innovations like pharmacogenetic testing. Furthermore, the increased involvement of governments, and funding for genomics propels the market in the region.
- The geographical representation of, middleware, and key participants together with the ongoing innovations in genetics testing technologies are other factors that help to account for the fact that North America dominates the market. Some legislation in the United States has fostered and promoted the use of pharmacogenetic testing as has been seen with other status. Increasing awareness of pharmacogenetic testing and the overall personalization of medicine along with considerable investment in the health care sector in North America is likely to sustain the continuing dominance in the global pharmacogenetic testing market.
Active Key Players in the Pharmacogenetic Testing Market:
-
23andMe (USA)
- Admera Health (USA)
- AltheaDx (USA)
- Asuragen, Inc. (USA)
- Genelex (USA)
- Illumina, Inc. (USA)
- Myriad Genetics, Inc. (USA)
- OneOme LLC (USA)
- Quest Diagnostics (USA)
- Laboratory Corporation of America Holdings (LabCorp) (USA)
- Thermo Fisher Scientific (USA)
- Roche Diagnostics (Switzerland), and Other Active Players
Key Industry Developments in the Pharmacogenetic Testing Market:
-
In May 2023, University of California San Francisco UCSF launched California's first Clinical Pharmacogenomics Program (CPP),integrating patient genomic data into healthcare decisions at UCSF Health. Led by Bani Tamraz, PharmD, PhD, and Lisa Kroon, PharmD,the program covers 15 genes and 56 drug therapies, enhancing treatment efficacy and safety through personalized medicine. Automated clinical decision-support systems in UCSF Health's electronic records prompt genetic testing recommendations or inform drug regimens based on genetic insights.
- In February 2023, MyRx, a new service from UF Health developed by pharmacists at the University of Florida College of Pharmacy, offers virtual pharmacogenetic testing consultations. It aims to provide patients with a convenient way to interpret their test results and optimize drug therapy.
- In May 2023, PerkinElmer Inc., a global provider of technology and service solutions, launched Revvity, Inc. as an independent provider of science-driven solutions leveraging advancements in diagnostics and life sciences to improve global well-being. Previously under PerkinElmer, Inc., Revvity Inc. serves diverse industries including pharmaceuticals, biotechnology, diagnostic laboratories, academia, and governmental organizations. The company offers a range of products including reagents, consumables, assays, instruments, and software
|
Global Pharmacogenetic Testing Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 13.20 Billion |
|
Forecast Period 2024-32 CAGR: |
9.12% |
Market Size in 2032: |
USD 28.95 Billion |
|
Segments Covered: |
By Technology |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Pharmacogenetic Testing Market by Technology
4.1 Pharmacogenetic Testing Market Snapshot and Growth Engine
4.2 Pharmacogenetic Testing Market Overview
4.3 Polymerase Chain Reaction (PCR)
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Polymerase Chain Reaction (PCR): Geographic Segmentation Analysis
4.4 DNA Sequencing
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 DNA Sequencing: Geographic Segmentation Analysis
4.5 Microarray
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Microarray: Geographic Segmentation Analysis
4.6 Other
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Other: Geographic Segmentation Analysis
Chapter 5: Pharmacogenetic Testing Market by Application
5.1 Pharmacogenetic Testing Market Snapshot and Growth Engine
5.2 Pharmacogenetic Testing Market Overview
5.3 Oncology
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oncology: Geographic Segmentation Analysis
5.4 Cardiovascular Diseases
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Cardiovascular Diseases: Geographic Segmentation Analysis
5.5 Neurology
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Neurology: Geographic Segmentation Analysis
5.6 Psychiatry
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Psychiatry: Geographic Segmentation Analysis
5.7 Pain Management
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Pain Management: Geographic Segmentation Analysis
5.8 Other
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Other: Geographic Segmentation Analysis
Chapter 6: Pharmacogenetic Testing Market by End User
6.1 Pharmacogenetic Testing Market Snapshot and Growth Engine
6.2 Pharmacogenetic Testing Market Overview
6.3 Hospitals and Clinics
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals and Clinics: Geographic Segmentation Analysis
6.4 Research Organizations
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Research Organizations: Geographic Segmentation Analysis
6.5 Diagnostic Laboratories
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Diagnostic Laboratories: Geographic Segmentation Analysis
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Pharmacogenetic Testing Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 23ANDME (USA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ADMERA HEALTH (USA)
7.4 ALTHEADX (USA)
7.5 ASURAGEN INC. (USA)
7.6 GENELEX (USA)
7.7 ILLUMINA INC. (USA)
7.8 MYRIAD GENETICS INC. (USA)
7.9 ONEOME LLC (USA)
7.10 QUEST DIAGNOSTICS (USA)
7.11 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP) (USA)
7.12 THERMO FISHER SCIENTIFIC (USA)
7.13 ROCHE DIAGNOSTICS (SWITZERLAND)
7.14 OTHER ACTIVE PLAYERS KEY PLAYERS
7.15 OTHER ACTIVE PLAYERS
Chapter 8: Global Pharmacogenetic Testing Market By Region
8.1 Overview
8.2. North America Pharmacogenetic Testing Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Technology
8.2.4.1 Polymerase Chain Reaction (PCR)
8.2.4.2 DNA Sequencing
8.2.4.3 Microarray
8.2.4.4 Other
8.2.5 Historic and Forecasted Market Size By Application
8.2.5.1 Oncology
8.2.5.2 Cardiovascular Diseases
8.2.5.3 Neurology
8.2.5.4 Psychiatry
8.2.5.5 Pain Management
8.2.5.6 Other
8.2.6 Historic and Forecasted Market Size By End User
8.2.6.1 Hospitals and Clinics
8.2.6.2 Research Organizations
8.2.6.3 Diagnostic Laboratories
8.2.6.4 Other
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Pharmacogenetic Testing Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Technology
8.3.4.1 Polymerase Chain Reaction (PCR)
8.3.4.2 DNA Sequencing
8.3.4.3 Microarray
8.3.4.4 Other
8.3.5 Historic and Forecasted Market Size By Application
8.3.5.1 Oncology
8.3.5.2 Cardiovascular Diseases
8.3.5.3 Neurology
8.3.5.4 Psychiatry
8.3.5.5 Pain Management
8.3.5.6 Other
8.3.6 Historic and Forecasted Market Size By End User
8.3.6.1 Hospitals and Clinics
8.3.6.2 Research Organizations
8.3.6.3 Diagnostic Laboratories
8.3.6.4 Other
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Pharmacogenetic Testing Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Technology
8.4.4.1 Polymerase Chain Reaction (PCR)
8.4.4.2 DNA Sequencing
8.4.4.3 Microarray
8.4.4.4 Other
8.4.5 Historic and Forecasted Market Size By Application
8.4.5.1 Oncology
8.4.5.2 Cardiovascular Diseases
8.4.5.3 Neurology
8.4.5.4 Psychiatry
8.4.5.5 Pain Management
8.4.5.6 Other
8.4.6 Historic and Forecasted Market Size By End User
8.4.6.1 Hospitals and Clinics
8.4.6.2 Research Organizations
8.4.6.3 Diagnostic Laboratories
8.4.6.4 Other
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Pharmacogenetic Testing Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Technology
8.5.4.1 Polymerase Chain Reaction (PCR)
8.5.4.2 DNA Sequencing
8.5.4.3 Microarray
8.5.4.4 Other
8.5.5 Historic and Forecasted Market Size By Application
8.5.5.1 Oncology
8.5.5.2 Cardiovascular Diseases
8.5.5.3 Neurology
8.5.5.4 Psychiatry
8.5.5.5 Pain Management
8.5.5.6 Other
8.5.6 Historic and Forecasted Market Size By End User
8.5.6.1 Hospitals and Clinics
8.5.6.2 Research Organizations
8.5.6.3 Diagnostic Laboratories
8.5.6.4 Other
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Pharmacogenetic Testing Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Technology
8.6.4.1 Polymerase Chain Reaction (PCR)
8.6.4.2 DNA Sequencing
8.6.4.3 Microarray
8.6.4.4 Other
8.6.5 Historic and Forecasted Market Size By Application
8.6.5.1 Oncology
8.6.5.2 Cardiovascular Diseases
8.6.5.3 Neurology
8.6.5.4 Psychiatry
8.6.5.5 Pain Management
8.6.5.6 Other
8.6.6 Historic and Forecasted Market Size By End User
8.6.6.1 Hospitals and Clinics
8.6.6.2 Research Organizations
8.6.6.3 Diagnostic Laboratories
8.6.6.4 Other
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Pharmacogenetic Testing Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Technology
8.7.4.1 Polymerase Chain Reaction (PCR)
8.7.4.2 DNA Sequencing
8.7.4.3 Microarray
8.7.4.4 Other
8.7.5 Historic and Forecasted Market Size By Application
8.7.5.1 Oncology
8.7.5.2 Cardiovascular Diseases
8.7.5.3 Neurology
8.7.5.4 Psychiatry
8.7.5.5 Pain Management
8.7.5.6 Other
8.7.6 Historic and Forecasted Market Size By End User
8.7.6.1 Hospitals and Clinics
8.7.6.2 Research Organizations
8.7.6.3 Diagnostic Laboratories
8.7.6.4 Other
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Global Pharmacogenetic Testing Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 13.20 Billion |
|
Forecast Period 2024-32 CAGR: |
9.12% |
Market Size in 2032: |
USD 28.95 Billion |
|
Segments Covered: |
By Technology |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
